Cascadian Therapeutics Inc (USA) news

   Watch this stock
Showing stories 1 - 10 of about 81   

Articles published

CASC 4.05 +0.17 (4.38%)
price chart
Here's Why Cascadian Therapeutics Inc (USA) (CASC) Shares Tumble 11%
Cascadian Therapeutics Inc (USA) (NASDAQ:CASC) announced that it intends to offer and sell shares of its common stock and Series E convertible preferred stock in concurrent but separate underwritten public offerings.
Cascadian Therapeutics Announces Proposed Concurrent Public Offerings of ...  GlobeNewswire (press release)
Cowen Dives in on Cascadian Therapeutics Inc (USA) (CASC) Following HER2CLIMB ...
Cowen analyst Boris Peaker weighed in on Cascadian Therapeutics Inc (USA) (NASDAQ:CASC) with a few insights after the company announced that following a recent meeting with the FDA and discussions with the Company's external Steering Committee, ...
Stock Update (NASDAQ:CASC): Cascadian Therapeutics Inc (USA) Announces ...
casc Cascadian Therapeutics Inc (USA) (NASDAQ:CASC) announced that its board of directors has approved a plan for a reverse split of the Company's common stock to increase its share price and reduce the number of authorized and outstanding shares.
Company Update (NASDAQ:CASC): Cascadian Therapeutics Inc (USA) Announces ...
casc Cascadian Therapeutics Inc (USA) (NASDAQ:CASC) announced that it intends to offer and sell shares of its common stock in an underwritten public offering.
Stock Update (NASDAQ:CASC): Cascadian Therapeutics Inc (USA) Receives ONT-380 ...
Cascadian Therapeutics (NASDAQ:CASC), a clinical-stage biopharmaceutical company, today announced that the ONT-380 program in advanced HER2+ metastatic breast cancer has received Fast Track designation from the U.S. Food and Drug ...
Cascadian Therapeutics Inc (USA) (NASDAQ:CASC) Likely to Breakout
Investors should take note of the 14% jump in the share price of Cascadian Therapeutics Inc (USA) (NASDAQ:CASC) yesterday on a traded volume of 2.01 million shares.
BRIEF-Mark Lampert says resigning from Cascadian Therapeutics' board
Feb 17 Citigroup Inc's board of directors cut Chief Executive Officer Michael Corbat's compensation by 6 percent last year after the bank missed financial targets and one-third of its voting shareholders disapproved of his prior pay package.
Cascadian Therapeutics Announces Approval of Nonproprietary Name “tucatinib ...
SEATTLE, Aug. 31, 2016 (GLOBE NEWSWIRE) -- Cascadian Therapeutics (NASDAQ:CASC), a clinical-stage biopharmaceutical company, today announced that the United States Adopted Names (USAN) Council and the International Nonproprietary Names ...
Healthcare Stocks on Investors' Radar -- Alkermes, Teleflex, Cascadian ...
This morning, Stock-Callers.com tracks the current performances of Alkermes PLC (NASDAQ: ALKS), Teleflex Inc. (NYSE: TFX), Cascadian Therapeutics Inc. (NASDAQ: CASC), and InspireMD Inc. (NYSE MKT: NSPR). According to research firm Charles ... The ...
Cascadian Therapeutics to Present at the Ladenburg Thalmann 2016 Healthcare ...
20, 2016 (GLOBE NEWSWIRE) -- Cascadian Therapeutics (NASDAQ:CASC), a clinical-stage biopharmaceutical company, today announced that Julie Eastland, Chief Financial Officer, will present a corporate overview at the Ladenburg Thalmann 2016 Healthcare ...